Phase I Study of Secondary Primary Tumor Prevention With Epidermal Growth Factor Receptor (EGFR), Tyrosine Kinase Inhibitor Erlotinib (OSI-774, Tarceva), and Cyclooxygenase-2 (COX-2) Inhibitor (Celecoxib) in Early Stage (Stage I/II) Squamous Cell Carcinoma of Head and Neck

Trial Profile

Phase I Study of Secondary Primary Tumor Prevention With Epidermal Growth Factor Receptor (EGFR), Tyrosine Kinase Inhibitor Erlotinib (OSI-774, Tarceva), and Cyclooxygenase-2 (COX-2) Inhibitor (Celecoxib) in Early Stage (Stage I/II) Squamous Cell Carcinoma of Head and Neck

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Mar 2017

At a glance

  • Drugs Celecoxib (Primary) ; Erlotinib (Primary)
  • Indications Head and neck cancer; Solid tumours
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Mar 2017 Planned End Date changed from 1 Feb 2017 to 1 Mar 2018.
    • 26 Feb 2016 Planned End Date changed from 1 Jan 2016 to 1 Feb 2017 as reported by ClinicalTrials.gov record.
    • 25 Mar 2015 Phase is changed from I/II to phase I.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top